Collectively, these findings demonstrate that AMIGO2 serves as a robust prognostic indicator in PAAD, with its elevated expression specifically associated with unfavorable clinical outcomes compared with other AMIGO family members or cancer types. This evidence concerns the gene AMIGO2 and pancreatic adenocarcinoma.